175 related articles for article (PubMed ID: 37867006)
1. Management of transfusion-dependent β-thalassemia (TDT): Expert insights and practical overview from the Middle East.
El-Beshlawy A; Dewedar H; Hindawi S; Alkindi S; Tantawy AA; Yassin MA; Taher AT
Blood Rev; 2024 Jan; 63():101138. PubMed ID: 37867006
[TBL] [Abstract][Full Text] [Related]
2. How I treat non-transfusion-dependent β-thalassemia.
Saliba AN; Musallam KM; Taher AT
Blood; 2023 Sep; 142(11):949-960. PubMed ID: 37478396
[TBL] [Abstract][Full Text] [Related]
3. New therapeutic targets in transfusion-dependent and -independent thalassemia.
Cappellini MD; Motta I
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):278-283. PubMed ID: 29222267
[TBL] [Abstract][Full Text] [Related]
4. Iron Chelation Therapy as a Modality of Management.
Aydinok Y
Hematol Oncol Clin North Am; 2018 Apr; 32(2):261-275. PubMed ID: 29458731
[TBL] [Abstract][Full Text] [Related]
5. Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation.
Motta I; Bou-Fakhredin R; Taher AT; Cappellini MD
Drugs; 2020 Jul; 80(11):1053-1063. PubMed ID: 32557398
[TBL] [Abstract][Full Text] [Related]
6. 2021 update on clinical trials in β-thalassemia.
Musallam KM; Bou-Fakhredin R; Cappellini MD; Taher AT
Am J Hematol; 2021 Nov; 96(11):1518-1531. PubMed ID: 34347889
[TBL] [Abstract][Full Text] [Related]
7. Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series.
Pinto VM; Forni GL
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233561
[TBL] [Abstract][Full Text] [Related]
8. Iron overload in thalassemia: different organs at different rates.
Taher AT; Saliba AN
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):265-271. PubMed ID: 29222265
[TBL] [Abstract][Full Text] [Related]
9. Iron Chelation for Iron Overload in Thalassemia.
Crisponi G; Nurchi VM; Lachowicz JI
Met Ions Life Sci; 2019 Jan; 19():. PubMed ID: 30855104
[TBL] [Abstract][Full Text] [Related]
10. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.
Marsella M; Borgna-Pignatti C
Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709
[TBL] [Abstract][Full Text] [Related]
11. Iron chelation therapy in the management of thalassemia: the Asian perspectives.
Viprakasit V; Lee-Lee C; Chong QT; Lin KH; Khuhapinant A
Int J Hematol; 2009 Nov; 90(4):435-445. PubMed ID: 19862602
[TBL] [Abstract][Full Text] [Related]
12. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications.
Farmaki K; Tzoumari I; Pappa C
Blood Cells Mol Dis; 2011 Jun; 47(1):33-40. PubMed ID: 21531154
[TBL] [Abstract][Full Text] [Related]
13. Challenges in chronic transfusion for patients with thalassemia.
Lal A
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):160-166. PubMed ID: 33275743
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
Hagag AA; Hamam MA; Taha OA; Hazaa SM
Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Kontoghiorghe CN; Kontoghiorghes GJ
Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
[TBL] [Abstract][Full Text] [Related]
16. Iron overload and iron-chelating therapy in hemoglobin E-beta thalassemia.
Olivieri NF; De Silva S; Premawardena A; Sharma S; Viens AM; Taylor CM; Brittenham GM; Weatherall DJ
J Pediatr Hematol Oncol; 2000; 22(6):593-7. PubMed ID: 11132236
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effects of calcium channel blockers plus iron chelation therapy versus chelation therapy only on iron overload in children and young adults with transfusion-dependent thalassemia: A randomized double-blind placebo-controlled trial.
Gupta V; Kumar I; Raj V; Aggarwal P; Agrawal V
Pediatr Blood Cancer; 2022 Jun; 69(6):e29564. PubMed ID: 35092347
[TBL] [Abstract][Full Text] [Related]
18. Thalassemia.
Aydinok Y
Hematology; 2012 Apr; 17 Suppl 1():S28-31. PubMed ID: 22507773
[TBL] [Abstract][Full Text] [Related]
19. Management of the aging beta-thalassemia transfusion-dependent population - The Italian experience.
Pinto VM; Poggi M; Russo R; Giusti A; Forni GL
Blood Rev; 2019 Nov; 38():100594. PubMed ID: 31416718
[TBL] [Abstract][Full Text] [Related]
20. Non-Transfusion-Dependent Thalassemia: A Panoramic Review.
Shash H
Medicina (Kaunas); 2022 Oct; 58(10):. PubMed ID: 36295656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
